ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is 61.12% higher on its value in year-to-date trading and has touched a low of $12.24 and a high of $25.73 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ACAD stock was last observed hovering at around $25.54 in the last trading session, with the day’s gains setting it 0.11% off its average median price target of $22.30 for the next 12 months. It is also 22.27% off the consensus price target high of $33.00 offered by 20 analysts, but current levels are -113.75% lower than the price target low of $12.00 for the same period.
Currently trading at $25.65, the stock is 16.08% and 26.41% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.15 million and changing 0.43% at the moment leaves the stock 43.70% off its SMA200. ACAD registered 49.91% gain for a year compared to 6-month gain of 73.55%. The firm has a 50-day simple moving average (SMA 50) of $6.07 and a 200-day simple moving average (SMA200) of -$19.46.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
The stock witnessed a 27.55% loss in the last 1 month and extending the period to 3 months gives it a 34.29%, and is 13.10% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.57% over the week and 3.45% over the month.
ACADIA Pharmaceuticals Inc. (ACAD) has around 540 employees, a market worth around $3.98B and $520.20M in sales. Profit margin for the company is -28.10%. Distance from 52-week low is 109.56% and -0.31% from its 52-week high. The company has generated returns on investments over the last 12 months (-56.50%).
ACADIA Pharmaceuticals Inc. (ACAD) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for ACADIA Pharmaceuticals Inc. (ACAD) is a “Overweight”. 20 analysts offering their recommendations for the stock have an average rating of 2.60, where 10 rate it as a Hold and 0 think it is a “Overweight”. 8 of the analysts rate the stock as a “Buy”. 2 analysts have rated the stock as a Sell or Underperform.
ACADIA Pharmaceuticals Inc. is expected to release its quarterly report on 08/02/2023.The EPS is expected to shrink by -27.70% this year
ACADIA Pharmaceuticals Inc. (ACAD) Top Institutional Holders
The shares outstanding are 162.26M, and float is at 161.70M with Short Float at 5.97%.
ACADIA Pharmaceuticals Inc. (ACAD) Insider Activity
A total of 38 insider transactions have happened at ACADIA Pharmaceuticals Inc. (ACAD) in the last six months, with sales accounting for 18 and purchases happening 20 times. The most recent transaction is an insider purchase by BAKER BROS. ADVISORS LP, the company’s Director. SEC filings show that BAKER BROS. ADVISORS LP bought 553,263 shares of the company’s common stock on May 24 at a price of $25.48 per share for a total of $14.1 million. Following the purchase, the insider now owns 39.32 million shares.
ACADIA Pharmaceuticals Inc. disclosed in a document filed with the SEC on May 23 that BAKER BROS. ADVISORS LP (Director) bought a total of 209,053 shares of the company’s common stock. The trade occurred on May 23 and was made at $25.41 per share for $5.31 million. Following the transaction, the insider now directly holds 38.81 million shares of the ACAD stock.
Still, SEC filings show that on May 22, BAKER BROS. ADVISORS LP (Director) acquired 134,206 shares at an average price of $24.57 for $3.3 million. The insider now directly holds 38,607,761 shares of ACADIA Pharmaceuticals Inc. (ACAD).
ACADIA Pharmaceuticals Inc. (ACAD): Who are the competitors?
The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 40.70% up over the past 12 months and Vanda Pharmaceuticals Inc. (VNDA) that is -37.27% lower over the same period. Johnson & Johnson (JNJ) is -12.70% down on the 1-year trading charts.